Apellis Pharmaceuticals, Inc. Common Stock

APLSNASDAQUSD
40.92 USD
0.03 (0.06%)🟢LIVE (AS OF 03:05 PM EDT)
🟢Market: OPEN
Open?$40.92
High?$40.94
Low?$40.91
Prev. Close?$40.94
Volume?1.6M
Avg. Volume?7.6M
VWAP?$40.92
Rel. Volume?0.21x
Bid / Ask
Bid?$40.91 × 100
Ask?$40.92 × 200
Spread?$0.01
Midpoint?$40.92
Valuation & Ratios
Market Cap?5.2B
Shares Out?127.8M
Float?108.2M
Float %?84.6%
P/E Ratio?228.82
P/B Ratio?14.14
EPS?$0.18
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.13Strong
Quick Ratio?2.69Strong
Cash Ratio?1.44Strong
Debt/Equity?1.23Moderate
ValuationRICHLY VALUED
Score
44/100
P/E?
228.8PRICEY
P/B?
14.14HIGH
P/S?
5.21FAIR
P/FCF?
116.3PRICEY
EV/EBITDA?
91.7HIGH
EV/Sales?
5.20FAIR
Returns & Efficiency
ROE?
6.2%FAIR
ROA?
2.1%WEAK
Cash Flow & Enterprise
FCF?$45.0M
Enterprise Value?$5.2B
News
Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Employees
733
Market Cap
5.2B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2017-11-09
Address
100 FIFTH AVENUE
WALTHAM, MA 02451
Phone: 617-977-5700